Stereoselective Enzymatic Synthesis of Heteroatom-Substituted Cyclopropanes by Brandenberg, Oliver F. et al.
Stereoselective Enzymatic Synthesis of Heteroatom-Substituted
Cyclopropanes
Oliver F. Brandenberg,† Christopher K. Prier,†,§ Kai Chen,† Anders M. Knight,‡ Zachary Wu,†
and Frances H. Arnold*,†
†Division of Chemistry and Chemical Engineering, California Institute of Technology, 1200 East California Boulevard, Pasadena,
California 91125, United States
‡Division of Biology and Bioengineering, California Institute of Technology, 1200 East California Boulevard, Pasadena, California
91125, United States
*S Supporting Information
ABSTRACT: The repurposing of hemoproteins for non-natural
carbene transfer activities has generated enzymes for functions
previously accessible only to chemical catalysts. With activities
constrained to speciﬁc substrate classes, however, the synthetic
utility of these new biocatalysts has been limited. To expand the
capabilities of non-natural carbene transfer biocatalysis, we
engineered variants of Cytochrome P450BM3 that catalyze the
cyclopropanation of heteroatom-bearing alkenes, providing valuable
nitrogen-, oxygen-, and sulfur-substituted cyclopropanes. Four or
ﬁve active-site mutations converted a single parent enzyme into
selective catalysts for the synthesis of both cis and trans heteroatom-
substituted cyclopropanes, with high diastereoselectivities and
enantioselectivities and up to 40 000 total turnovers. This work highlights the ease of tuning hemoproteins by directed
evolution for eﬃcient cyclopropanation of new substrate classes and expands the catalytic functions of iron heme proteins.
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The cyclopropane ring is an important building block inorganic synthesis and a structural motif in diverse
bioactive compounds.1,2 Especially notable are heteroatom
(nitrogen, oxygen, or sulfur)-substituted cyclopropanes, which
appear in many natural products3 and biosynthetic inter-
mediates (Scheme 1A).4 In pharmaceuticals, introduction of
cyclopropylamines can substantially improve physicochemical
and pharmacokinetic properties,5 and the cyclopropylamine
functionality appears in the class of hepatitis C virus protease
inhibitors represented by simeprevir6 and grazoprevir.7 Novel
biomaterials have also been constructed using β-amino-
cyclopropane carboxylic acids (β-ACCs) and related com-
pounds as rigid building blocks in synthetic peptides.8,9
Heteroatom-bearing cyclopropanes are additionally useful
synthetic intermediates that engage in a variety of ring-opening
transformations.10−13
Enantiomerically enriched cyclopropylamines are most
commonly synthesized via Curtius or Hofmann rearrangements
from the corresponding enantioenriched cyclopropylcarboxylic
acids or amides.14,15 Chiral cyclopropylamines and cyclo-
propanols have also been synthesized via asymmetric phase-
transfer catalysis16,17 and enzymatic resolution.18,19 Alterna-
tively, forming the cyclopropane ring with control over
stereochemistry by catalytic, enantioselective cyclopropanation
of heteroatom-substituted alkenes represents a powerful
approach to this class of compounds (Scheme 1B). Such
reactions have been performed via carbene transfer with chiral
ruthenium,20−24 rhodium,25−27 and copper11,27 catalysts.
Aminocyclopropanes have also been accessed via alkene
cyclopropanation with nitro-substituted carbenoids, followed
by reduction of the nitro group.28,29 However, many of the
existing methods exhibit low catalyst turnover, proceed with
only moderate levels of stereocontrol, are limited to speciﬁc
substrate types, or require precious metals (e.g., Ru, Rh).
Furthermore, these methods generally provide only the trans-
cyclopropane products with high diastereoselectivity and
enantioselectivity.
We and others have demonstrated that hemoproteins can be
engineered to perform cyclopropanation reactions of oleﬁns via
carbene transfer.30−35 The synthetic utility of these “carbene
transferases”, engineered by directed evolution of cytochromes
P450, myoglobins, and other proteins, has been demonstrated
through preparative-scale syntheses of cyclopropane-containing
pharmaceutical precursors.36−38 To date, however, almost all
cyclopropanation reactions catalyzed by hemoproteins have
required arene-substituted (styrenyl) oleﬁns. In a ﬁrst step
toward broadening the substrate scope of enzyme-catalyzed
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cyclopropanation, we demonstrated recently that natural
hemoprotein diversity can be leveraged to identify and engineer
Cytochrome P450 and globin variants for the stereoselective
cyclopropanation of unactivated, aliphatic alkenes,39 an activity
previously achieved only by hemoproteins containing an
artiﬁcial iridium co-factor.40−42 Gober et al. also recently
reported engineered Cytochrome P450 variants for the
cyclopropanation of dehydroalanine residues in thiopeptides,43
thereby enabling a non-natural modiﬁcation of a complex
natural product. We reasoned that diverse heteroatom-
substituted alkenes should be suitable coupling partners for
electrophilic metal carbenoids derived from the reaction of
diazo esters with genetically encoded heme proteins. This
reaction would extend the scope of biocatalytic cyclo-
propanation to encompass a new class of synthetically
important cyclopropanes (Scheme 1B). Here, we describe the
directed evolution of Cytochrome P450 variants that cyclo-
propanate heteroatom-bearing alkenes to yield chiral N-, O-,
and S-cyclopropanes. The resulting enzymes outperform
existing small-molecule catalysts, especially for challenging cis-
selective cyclopropanation reactions.
To gauge the potential of enzymatic heteroatom-substituted
cyclopropane synthesis, we ﬁrst tested a set of hemoproteins for
cyclopropanation of N-vinylphthalimide (1) with ethyl
diazoacetate (EDA, 2) as the carbene precursor (Figure 1), a
reaction performed by free heme with a total turnover number
(TTN) of 3 and 28:72 diastereomeric ratio (dr) (cis:trans) (see
Table S2 in the Supporting Information). Enzymatic reactions
were carried out with whole Escherichia coli (E. coli) cells
expressing the hemoprotein variants and were analyzed for
reaction yield and stereoselectivity (see Table S2). Variants of
Cytochrome P450BM3 from Bacillus megaterium were found to
be active catalysts for synthesis of cyclopropane adduct 3,
including several “P411” variants that feature a cysteine-to-
serine mutation at the residue ligating the iron center.31 E. coli
expressing variant P411BM3-CIS
31 demonstrated promising
diastereoselectivity (88:12 cis:trans), and this protein was
selected for further engineering by directed evolution to
enhance its catalytic activity.
To increase the activity of P411BM3-CIS we performed
parallel site-saturation mutagenesis at active site residues V87,
L181, I263, T268, L437, and T438, positions previously shown
to inﬂuence P450-catalyzed non-natural carbene and nitrene
transfer activities (see Figure S3 in the Supporting
Information)30,36 and screened the resulting libraries for
cyclopropanation on N-vinylphthalimide with EDA. Several
mutations at these positions yielded improved catalysts (see
Table S3 in the Supporting Information); in addition, we found
that mutation I263G, located above the heme co-factor,
reversed diastereoselectivity from favoring cis-3 (88:12) to
favoring trans-3 (28:72), as the mutation I263A does in P450-
catalyzed styrene cyclopropanation.30 To identify the optimal
Scheme 1. (A) Examples of Cyclopropylamines and
Cyclopropanols in Natural Products, Pharmaceuticals, and
Biomaterials; (B) Proposed Enzymatic Synthesis of Chiral
Heteroatom-Substituted Cyclopropanesa
aEnzymatic carbene transfer to heteroatom-substituted alkenes
generates heteroatom-substituted cyclopropanes in a single step with
control over stereoselectivity.
Figure 1. Directed evolution of P411BM3-CIS for cis- and trans-
selective cyclopropanation of N-vinylphthalimide (1). Yields were
determined by liquid chromatography (LC) analysis. Enantioselectiv-
ities are given for the respective diastereomers. (A) Evolutionary
lineage for cis-selective N-vinylphthalimide cyclopropanation. Reac-
tions were performed with whole E. coli cells at OD600 = 30 expressing
the indicated variants, 30 mM N-vinylphthalimide (1), and 60 mM
EDA (2) under anaerobic conditions. (B) Evolutionary lineage for
trans-selective N-vinylphthalimide cyclopropanation. Reactions were
performed with whole E. coli cells at OD600 = 30 expressing the
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combination of activating mutations, we screened a recombi-
nation library encompassing a set of eight beneﬁcial single
active-site mutations (Table S3). From this library, we
identiﬁed two variants with improved activity relative to
P411BM3-CIS as well as complementary trans and cis
diastereoselectivity: variant P411BM3-CIS L437F T438Q favors
the cis cyclopropane product (94:6 dr, 94% enantiomeric excess
(ee)), while P411BM3-CIS I263G L437F favors the trans (27:73
dr, −64% ee) (Figure 1).
We next chose to optimize the cis- and trans-selective P411
variants separately, with the aim of evolving highly active
catalysts for the selective synthesis of each cyclopropane
diastereomer. For the cis-selective variant, iterative site-
saturation mutagenesis and screening delivered variant
P411BM3-CIS L437F T438Q L75Y L181I; we refer to this
evolved cis-selective vinyl amide cyclopropanation catalyst as
P411-VACcis. This enzyme is a highly active and selective
catalyst: when used in whole E. coli cells (with typical enzyme
concentrations of 0.8 to 0.9 μM), P411-VACcis provides almost
full conversion at up to 30 mM substrate loading with 35 000
TTN, 97:3 dr and 97% ee (Figure 1A). Up to 40 000 TTN
were obtained at higher substrate or lower catalyst loadings (see
Figure S4 in the Supporting Information), which places P411-
VACcis among the most active carbene transfer hemoproteins
described to date.31,33,44
For the trans-selective variant P411BM3-CIS I263G L437F,
further site-saturation mutagenesis and screening yielded
variant P411BM3-CIS I263G L437F V87L L181R, which we
term P411-VACtrans. In whole E. coli cells, this variant catalyzes
cyclopropanation of N-vinylphthalimide with EDA in 86% yield
with 980 TTN, 3:97 dr, and 92% ee (Figure 1B).
Kinetic analyses revealed that, in the whole-cell context,
P411-VACcis displays an apparent turnover frequency (TOF) of
390 min−1 over the ﬁrst 10 min and maintains activity over
several hours (see Figure 2, as well as Figure S5 in the
Supporting Information). This long catalyst lifetime is notable
among hemoprotein carbene transferases, as many of those
described to date suﬀer from rapid inactivation through transfer
of the reactive carbene intermediate to protein side chains or
the porphyrin co-factor.44,45 Indeed, such “burnout” behavior
was observed for the evolved trans-selective variant P411-
VACtrans, which shows much lower TTNs than P411-VACcis and
loses its catalytic activity after 30−60 min (Figure 2B). Thus,
P411-VACcis may possess an active site structure that eﬀectively
directs iron carbenoid reactivity toward the intended alkene
substrate while suppressing self-alkylation. We anticipate that
future work to identify biochemical and structural determinants
responsible for the long catalyst lifetime of P411-VACcis (and
the shorter lifetime of P411-VACtrans) will aid the design of
highly active carbene transfer catalysts for other substrates and
reaction classes.
Cyclopropanation of heteroatom-substituted alkenes also
proceeds with the puriﬁed P411 enzymes, although with
signiﬁcantly lower eﬃciencies. In vitro, P411-VACcis catalyzes
N-vinylphthalimide cyclopropanation with a TOF of 22 min−1
and 31% yield, 620 TTN, 91:9 dr and 93% ee, demonstrating
signiﬁcant decreases in all parameters, compared to whole-cell
conditions (see Figure 2A, as well as Table S4 in the
Supporting Information). This agrees with previous ﬁndings
of enhanced hemoprotein carbene transfer activity in whole
cells, compared to puriﬁed protein,31,44,46 which we speculate is
due to reduced EDA-induced protein alkylation and
inactivation in the intact cells. Catalyst activity and lifetime is
thus strongly inﬂuenced by the reaction (cellular) environment,
as well as the protein sequence.
To demonstrate the synthetic utility of the evolved cis- and
trans-selective variants, we performed preparative-scale syn-
theses with N-vinylphthalimide and EDA. From a 4.0 mmol
reaction with P411-VACcis, cyclopropane 3a was isolated in
96% yield (996 mg) with 97:3 dr and 97% ee, demonstrating
facile gram-scale cyclopropane synthesis enabled by this variant.
Using P411-VACtrans, a 0.125 mmol scale reaction delivered
88% yield (28.5 mg) of the trans-cyclopropane 3b with 3:97 dr
and 92% ee (Scheme 2). The reactions did not require a slow
addition of substrates, and products were readily obtained in
high purity after extraction from the aqueous phase and silica
ﬂash column chromatography. Absolute conﬁgurations were
assigned by crystallization of the trans-cyclopropane 3b, which
revealed the compound to be the (1S, 2S) isomer (see Figure
S1 in the Supporting Information). The cyclopropanation of
styrene by P411-VACcis was used to assign the conﬁguration of
Figure 2. Kinetics of Cytochrome P411-catalyzed N-vinylphthalimde
cyclopropanation. (A) Apparent turnover frequency observed with
puriﬁed protein and whole-cell catalysts (“n.d.” = not determined). (B)
Reaction kinetics of whole-cell catalysts expressing P411-VACcis or
P411-VACtrans, recorded over 6 h. Results are the average of duplicate
reactions at each time point. Reaction conditions for P411-VACcis and
P411-VACtrans are as shown in Figure 1.
Scheme 2. Syntheses of Phthalimide-Protected
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the cis-cyclopropane 3a as (1S, 2R) (see Figure S2 in the
Supporting Information).
We next tested the substrate scopes of P411-VACcis and
P411-VACtrans across a range of structurally diverse N-, O-, and
S-substituted oleﬁns. We were delighted to ﬁnd that P411-
VACtrans performs highly stereoselective cyclopropanation of N-
vinylcaprolactam, N-vinylpyrrolidone, and N-methyl-N-vinyl-
acetamide, delivering the corresponding cyclopropanes in
57%−65% isolated yield with up to 4:96 dr and 95% ee (see
Table 1). Variant P411-VACcis also catalyzes cyclopropanation
of these substrates, but with lower levels of enantiocontrol
between 4% ee and 59% ee (see Figure S6 in the Supporting
Information). The results varied across other substrates tested:
for phenyl vinyl sulﬁde, both catalysts failed to achieve good
diastereoselectivity or enantioselectivity. For phenyl vinyl ether,
we observed a switch in diastereoselectivity, with P411-VACcis
selectively providing the trans product (22:78 dr, 95% ee),
while P411-VACtrans yielded the cis product with low selectivity
(61:39 dr, 26% ee) (see Figure S6). Lastly, both variants accept
the bulky N-vinylcarbazole as a substrate, with P411-VACtrans
(6:94 dr, 94% ee) again outperforming P411-VACcis (44:56 dr,
22% ee) in both diastereoselectivity and enantioselectivity.
To improve the performance of P411-VACcis across these
diﬀerent substrates, we performed one additional round of
mutagenesis and screening. A small library of 14 P411-VACcis
variants with single active-site mutations at residues V87, I263,
E267, and A328 (see Table S5 in the Supporting Information)
was screened for cyclopropanation activity on N-vinyl-
pyrrolidone, N-methyl-N-vinylacetamide, phenyl vinyl sulﬁde,
and phenyl vinyl ether. This approach yielded P411-VACcis
variants showing improvements in both dr and ee across these
substrates (Figure S6 and Table 1). For N-vinylpyrrolidone and
N-vinylcaprolactam, introduction of the V87T mutation
increased enantioselectivity from 4% ee to 74% ee and from
59% ee to 88% ee, respectively. Interestingly, the V87T
mutation also turned P411-VACcis into a competent catalyst for
cis-selective cyclopropanation of phenyl vinyl ether (72:28 dr,
87% ee). For N-methyl-N-vinylacetamide, ee was increased
from 28% to 97% through an E267N mutation. For cis-selective
cyclopropanation of phenyl vinyl sulﬁde, an A328N mutation
improved diastereoselectivity from 59:41 dr to 84:16 dr while
increasing the ee from 39% to 90%, thereby delivering a
cyclopropane core allowing extensive further functionalization
with high selectivity.47 Moreover, this approach yielded P411-
VACcis variants with good to excellent diastereoselectivities and
enantioselectivities for the trans-selective cyclopropanation of
phenyl vinyl ether and phenyl vinyl sulﬁde, through a V87I and
V87F mutation, respectively (Table 1, Figure S6). We thereby
generated a panel of P411 variants delivering diverse
heteroatom-substituted cyclopropanes with good to excellent
dr and ee (Table 1). Because high-resolution protein structures
of these variants are currently lacking, it is diﬃcult to speculate
on the factors steering their enzymatic activity and cis- versus
trans-selectivity. We note, however, the important role of
position 87 in controlling diastereo- and enantioselectivity, as
previously reported.39,48,49 Given the malleability of the
P411BM3 active site observed in our studies, we expect that
the variants described here can be optimized further for highly
selective cyclopropanation of other, related substrates.
In summary, this work demonstrates that Cytochrome P411
can synthesize heteroatom-bearing cyclopropanes, which is a
valuable product class that has been widely studied for their
unique physical properties as well as pharmaceutical
applications and was previously inaccessible by enzymatic
cyclopropanation. The evolved P411 variants provide N,O,S-
cyclopropanes with high diastereoselectivities and enantiose-
lectivities, function under mild reaction conditions (at room
temperature in an aqueous buﬀer), and provide higher total
turnovers than reported for chemocatalysts for these trans-
formations (no more than 400 TTN).26 Together with recent
reports from this laboratory and others demonstrating
enzymatic cyclopropanation of unactivated, aliphatic alkenes39
Table 1. Substrate Scope of cis- and trans-Selective
Heteroatom-Substituted Alkene Cyclopropanationa
aReactions were performed on 0.125 mmol scale with whole E. coli
cells at OD600 = 50, 5 mM alkene, and 10 mM EDA. Isolated yields are
reported. Enantioselectivities are given for the major diastereomers.
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and complex natural products,43 this work demonstrates that
hemoproteins are not limited to styrenyl substrates. The P411
catalysts, which consist of an iron co-factor and a protein
scaﬀold produced in bacterial cells without need for
puriﬁcation, make these reactions a sustainable alternative to
approaches requiring precious metals. Furthermore, the enzyme
catalysts can go beyond existing chemical catalysts to generate
the cis-cyclopropanes with high stereoselectivity. This ex-
pansion of enzymatic activity from model substrates (styrenes)
to more diverse and functionalized starting materials such as
vinylamides will broaden the scope and potential applications of
non-natural biocatalysis in synthetic biology.
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